2
Clinical Trials associated with Insulin Aspart Biosimilar (YiChang HEC ChangJiang Pharmaceutical )比较门冬胰岛素注射液与诺和锐?在健康男性受试者中的药代动力学(PK)和药效动力学(PD)研究
[Translation] A pharmacokinetic (PK) and pharmacodynamic (PD) study comparing insulin aspart injection with NovoRapid in healthy male subjects
采用葡萄糖钳夹技术在健康男性志愿者中单剂量皮下注射门冬胰岛素注射液与诺和锐®的药效学和药代动力学性质,并评价两种制剂间的生物等效性。以及评价宜昌东阳光长江药业股份有限公司生产的门冬胰岛素注射液的安全性。
[Translation] To evaluate the pharmacodynamics and pharmacokinetic properties of insulin aspart injection and NovoRapid® after a single subcutaneous injection in healthy male volunteers using glucose clamp technology, and to evaluate the bioequivalence between the two preparations. And to evaluate the safety of insulin aspart injection produced by Yichang East Sunshine Changjiang Pharmaceutical Co., Ltd.
多中心、开放、随机、阳性药物平行对照试验,评价门冬胰岛素30注射液与诺和锐30的有效性及安全性
[Translation] A multicenter, open, randomized, positive drug parallel controlled trial to evaluate the efficacy and safety of insulin aspart 30 injection and NovoRapid 30
通过24 周非劣效性研究,评价由宜昌东阳光长江药业股份有限公司生产的门冬胰岛素30 注射液(RD10046)在2 型糖尿病患者中有效性及安全性
[Translation] A 24-week non-inferiority study was conducted to evaluate the efficacy and safety of insulin aspart 30 injection (RD10046) produced by Yichang East Sunshine Changjiang Pharmaceutical Co., Ltd. in patients with type 2 diabetes.
100 Clinical Results associated with Insulin Aspart Biosimilar (YiChang HEC ChangJiang Pharmaceutical )
100 Translational Medicine associated with Insulin Aspart Biosimilar (YiChang HEC ChangJiang Pharmaceutical )
100 Patents (Medical) associated with Insulin Aspart Biosimilar (YiChang HEC ChangJiang Pharmaceutical )
100 Deals associated with Insulin Aspart Biosimilar (YiChang HEC ChangJiang Pharmaceutical )